Search

Displaying results 2011 - 2020 of 3735 in total
  1. Drug

    Aluminium monostearate

    go.drugbank.com/drugs/DB01375
    Experimental

    Aluminium monostearate is a salt of stearic acid and aluminium with the molecular formula Al(OH)2C18H35O2. Also known as dihydroxyaluminium or dihydroxy(stearato)aluminium, it is used to form gels in the packaging of pharmaceuticals and ...

  2. Drug

    Midomafetamine

    go.drugbank.com/drugs/DB01454
    IllicitInvestigational

    An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug...

    Categories: Serotonin Receptor Agonists, Serotonin 5-HT2 Receptor Agonists
  3. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are i...

    Categories: P-glycoprotein substrates
  4. Drug

    Didesmethylrocaglamide

    go.drugbank.com/drugs/DB15496
    Experimental

    Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their inse...

  5. Target

    Nischarin

    go.drugbank.com/bio_entities/BE0003580
    TargetHumans

    Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling.

    Synonyms: Imidazoline receptor 1, Imidazoline-1 receptor
  6. Drug

    Ursodeoxycholic acid

    go.drugbank.com/drugs/DB01586
    ApprovedInvestigational

    Ursodeoxycholic acid (UDCA), also known as ursodiol, is a naturally-occurring bile acid that constitutes a minor fraction of the human bile acid pool. UDCA has been used to treat liver disease for decades: its first use in traditional me...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 Enzyme Inducers
  7. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. … [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g.

    Categories: Calcitonin Gene-Related Peptide Receptor Antagonists, P-glycoprotein substrates
  8. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in Septemb...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  9. Drug

    Hepatitis B Vaccine (Recombinant)

    go.drugbank.com/drugs/DB11627
    ApprovedInvestigationalWithdrawn

    Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form...

  10. Target

    Hypoxia-inducible factor 1

    go.drugbank.com/bio_entities/BE0010297
    TargetHumans

    Forms heterodimers with the aryl hydrocarbon receptor (AHR) to mediate the transcriptional response to xenobiotics by binding xenobiotic response elements (XREs) or dioxin response elements (DREs) in target

    Polypeptides: Aryl hydrocarbon receptor nuclear translocatorSynonyms: Dioxin receptor, nuclear translocator